Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability

Purpose: Most breast cancers have chromosomal instability that seems related to defective mitotic spindle checkpoints. Because the molecular basis of this defect is unknown, we evaluated breast cancer cell lines and tissues for possible defects involving the major mitotic checkpoint genes responsible for maintaining chromosomal stability. Experimental Design: We analyzed sequences and expression levels (RNA and protein) of eight major spindle checkpoint genes (MAD1L1, MAD2L1, MAD2L2, BUB1, BUB1B, BUB3, CDC20, and TTK) in a panel of 12 breast cancer cell lines, most with established genetic instability and defective spindle damage checkpoint response. mRNA levels of these genes were also measured in primary tumor samples, and immunohistochemical staining was used to evaluate BUB1B protein levels in a panel of 270 additional cases of breast cancer. Results: No functionally significant sequence variations were found for any of the eight genes in the breast cancer cell lines with chromosomal instability. More surprisingly, the mRNA and protein levels for these checkpoint genes are significantly higher in the genetically unstable breast cancer cell lines and in high-grade primary breast cancer tissues than in the stable (and checkpoint proficient) MCF-10A and normal mammary epithelial cells, or in normal breast tissues. In fact, overexpression of the BUB1B protein is a marker that recognizes nearly 80% of breast cancers in paraffin-embedded tissues. Conclusions: Defective mitotic spindle checkpoints in breast cancer are most likely not caused by low expression or mutations of these eight checkpoint genes. High levels of these particular transcripts could represent a cellular compensation for defects in other molecular components of the mitotic spindle damage checkpoint, and increased expression of these genes might be markers of breast cancers with chromosomal instability.

[1]  Bert Vogelstein,et al.  Mutations of mitotic checkpoint genes in human cancers , 1998, Nature.

[2]  R. Goorha,et al.  The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. , 1999, Genomics.

[3]  E. Petty,et al.  Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells , 2000, Genes, chromosomes & cancer.

[4]  E. Petty,et al.  Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines. , 2000, Cancer letters.

[5]  W. Gerald,et al.  MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells , 2001, Nature.

[6]  R. Barkardottir,et al.  Mutation analysis of the CHK2 gene in breast carcinoma and other cancers , 2001, Breast Cancer Research.

[7]  A. Yoshimura,et al.  Genomic structure of the human MAD2 gene and mutation analysis in human lung and breast cancers. , 2001, Lung cancer.

[8]  R. C. Johnston,et al.  Distinct chromosome segregation roles for spindle checkpoint proteins. , 2002, Molecular biology of the cell.

[9]  S. Tsao,et al.  Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. , 2002, Cancer research.

[10]  R. Barkardottir,et al.  Mutation analysis of the CHK 2 gene in breast carcinoma and other cancers , 2002 .

[11]  M. Shichiri,et al.  Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. , 2002, Cancer research.

[12]  Carl W. Miller,et al.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors , 2002, Genes, chromosomes & cancer.

[13]  E. Gabrielson,et al.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. , 2002, The American journal of pathology.

[14]  Wenge Lu,et al.  hBUB1 defects in leukemia and lymphoma cells , 2002, Oncogene.

[15]  F. McKeon,et al.  Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. , 2003, Cancer cell.

[16]  C. Perou,et al.  Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.

[17]  Geert J P L Kops,et al.  Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Gabrielson,et al.  Mucinous Cancers have Fewer Genomic Alterations than More Common Classes of Breast Cancer , 2002, Breast Cancer Research and Treatment.

[19]  R. Mahmood,et al.  Slippage of Mitotic Arrest and Enhanced Tumor Development in Mice with BubR1 Haploinsufficiency , 2004, Cancer Research.

[20]  Yudong D. He,et al.  A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.

[21]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[22]  M. Stampfer,et al.  Growth of normal human mammary cells in culture , 1980, In Vitro.